Skip to market wire
Back to Market返回行情

ANTX AN2 Therapeutics, Inc.

USHealthcare
$5.63-3.10%ClosedMarket Cap: $202.8M

As of 2026-08-24

Why ANTX matters now

AN2 Therapeutics, Inc. (ANTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.63 with -3.10% on the session and $202.8M in market capitalization; recent performance reads 1-month +9.89% and YTD +338.60%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.0M, and EPS of $-0.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.8%.

The latest indexable market news headline is "AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Williams Sarah Joanne filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.08

P/S

0.00

EV/EBITDA

-2.33

DCF Value

$0.59

FCF Yield

-22.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-52.3%

ROA

-39.5%

ROIC

-45.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-10.0M$-0.29
Q4 2025$0.00$-8.7M$-0.29
FY 2025$0.00$-35.2M$-1.16
Q3 2025$0.00$-9.4M$-0.31

Analyst Ratings

Consensus

Buy

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$9.00 - $9.00

Strong Buy: 0Buy: 1Hold: 0Sell: 0Strong Sell: 0
Leerink PartnersOutperform
2026-05-14

Trading Activity

Insider Trades

Williams Sarah Joanneofficer: Principal Accounting Officer
Sell2026-06-02
Martin Patricia A.director
Sell2026-04-10
Marks Gilbert Lynndirector
Sell2026-04-10
Aziz Kabeerdirector
Sell2026-04-10
Easom Ericdirector, officer: Chief Executive Officer
Sell2026-03-23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

-0.98

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.